McDermott Will & Emery Advises Innate Pharma on New Capital Increase
January 14, 2025
January 14, 2025
CHICAGO, Illinois, Jan. 14 -- McDermott Will and Emery, a law firm, issued the following news release:
McDermott Will & Emery has advised biotechnology company Innate Pharma on an agreement with the Institute for Follicular Lymphoma Innovation (IFLI) to explore the clinical potential of IPH6501, Innate's anti-CD20 ANKET(R) in follicular lymphoma, under which IFLI has invested USD 3 million in new Innate Pharma shares.
The IFLI may also invest up to USD 4.9 mill . . .
McDermott Will & Emery has advised biotechnology company Innate Pharma on an agreement with the Institute for Follicular Lymphoma Innovation (IFLI) to explore the clinical potential of IPH6501, Innate's anti-CD20 ANKET(R) in follicular lymphoma, under which IFLI has invested USD 3 million in new Innate Pharma shares.
The IFLI may also invest up to USD 4.9 mill . . .